Home » USA Broker Ratings » GlaxoSmithKline PLC – Consensus Indicates Potential 13.8% Upside

GlaxoSmithKline PLC – Consensus Indicates Potential 13.8% Upside

GlaxoSmithKline PLC with ticker code (GSK) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 51 and 42.1 and has a mean target at 47.7. Given that the stocks previous close was at 41.92 this is indicating there is a potential upside of 13.8%. The day 50 moving average is 41.54 and the 200 moving average now moves to 42.82. The company has a market capitalisation of $103,161m. Find out more information at: http://www.gsk.com

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; and Sanofi SA. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Join us on our new LinkedIn page

Follow us on LinkedIn